TL;DR: Uncommon Therapeutics is a Y Combinator Winter 2025 startup A Disease Focused Biotech, Building Multiple Billion Dollar Drugs, currently active with a team of 2.
A Disease Focused Biotech, Building Multiple Billion Dollar Drugs
Last verified:
Our founder Noah, an experienced tech entrepreneur, was directly impacted by a severe genetic disease when his daughter was diagnosed with Rett Syndrome, a disease that afflicts 1 in 10,000 girls. Using an innovative polytherapy strategy, we’ve successfully improved her quality of life, and have designed new therapeutics that each could be worth billions and together could deliver a cure.
Built by LemStudio
Yes. Uncommon Therapeutics was funded by Y Combinator in the Winter 2025 batch. A Disease Focused Biotech, Building Multiple Billion Dollar Drugs
Our founder Noah, an experienced tech entrepreneur, was directly impacted by a severe genetic disease when his daughter was diagnosed with Rett Syndrome, a disease that afflicts 1 in 10,000 girls. Using an innovative polytherapy strategy, we’ve successfully improved her quality of life, and have designed new therapeut…
Uncommon Therapeutics was part of Y Combinator's Winter 2025 batch.
Uncommon Therapeutics has a team of 2 people according to Y Combinator's directory.
Uncommon Therapeutics is currently listed as Active with a team of 2 in Y Combinator's directory.
Loading interactive view…